BBA
ACHL

Baker Bros. Advisors’s Achilles Therapeutics ACHL Stock Holding History

Baker Bros. Advisors’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,108,767
Closed -$904K – 97
2024
Q2 		$904K Sell
1,108,767
-100,008
-8% -$87.9K 0.01% 88
2024
Q1 		$1.51M Sell
1,208,775
-894,017
-43% -$964K 0.02% 76
2023
Q4 		$1.87M Sell
2,102,792
-454,357
-18% -$390K 0.02% 72
2023
Q3 		$2.33M Hold
2,557,149
– – 0.01% 82
2023
Q2 		$2.42M Sell
2,557,149
-34,217
-1% -$32.5K 0.01% 91
2023
Q1 		$2.48M Hold
2,591,366
– – 0.01% 88
2022
Q4 		$2.33M Hold
2,591,366
– – 0.01% 96
2022
Q3 		$5.86M Hold
2,591,366
– – 0.04% 72
2022
Q2 		$6.53M Hold
2,591,366
– – 0.04% 72
2022
Q1 		$7.62M Hold
2,591,366
– – 0.04% 73
2021
Q4 		$13M Hold
2,591,366
– – 0.06% 70
2021
Q3 		$20.2M Hold
2,591,366
– – 0.09% 62
2021
Q2 		$25.4M Hold
2,591,366
– – 0.11% 61
2021
Q1 		$42.9M Buy
+2,591,366
New +$42.9M 0.19% 44

Other funds holding ACHL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Baker Bros. Advisors's ACHL Position: Q3 2024 in Review

Baker Bros. Advisors sold out of Achilles Therapeutics (ACHL) in Q3 2024, closing a stake of 1,108,767 shares — an estimated $904K sold.

Baker Bros. Advisors first reported a position in ACHL in Q1 2021 and held it in 14 quarters. The position peaked at $42.9M in Q1 2021. 22 funds tracked by Wall St. Rank hold ACHL as of Q3 2024.

  • Baker Bros. Advisors reported no remaining Achilles Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Baker Bros. Advisors sold 1,108,767 Achilles Therapeutics shares in Q3 2024, an estimated $904K.
  • Baker Bros. Advisors first reported a position in Achilles Therapeutics in Q1 2021 and held it in 14 quarters.
  • Baker Bros. Advisors's Achilles Therapeutics position peaked at $42.9M in Q1 2021.
  • 22 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q3 2024.

Based on Baker Bros. Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.